Sterile manufacturing, built for oncology injectables

A single, centrally managed manufacturing site in the MIDC Tarapur industrial estate, Boisar, Maharashtra, registered under DUNS 915076185. Consolidating sterile injectable and oral solid dose production on one site keeps the quality system, environmental monitoring program, and regulatory inspection history under one roof, rather than split across contract sites.

The plant runs four dosage-form lines: lyophilized (freeze-dried) sterile injectables, liquid sterile injectables, tablets, and capsules, plus active pharmaceutical ingredient (API) synthesis supplied through group company MacChem. Oncology, anesthesia, and critical-care injectables account for the largest share of sterile output; the tablet and capsule lines carry general and supportive-care formulations.

Manufacturing at Tarapur runs under process controls aligned to EU-GMP and WHO-GMP. The plant's GMP certification with ANVISA (Brazil) was renewed in January 2026, reported by Pharma India Magazine. A full register of accreditations (detailed and being-digitized) is maintained on the Quality page, including EU-GMP, INVIMA (Colombia), UAE Ministry of Health, NHRA Bahrain, and WHO-GMP.